Biolase (NSDQ:BIOL) and Auris Surgical Robotics said they’ve inked a deal to collaborate on developing a cataract-removal ophthalmologic robot.
The deal calls for the companies to combine Irvine, Calif.-based Biolase’s WaterLase cutting technology with a new robotics system from Redwood City, Calif.-based Auris. The 2 firms are seeking to improve the precision and safety of cataract-removal surgery and are prototyping the device.
“For cutting precision, system compatibility, and lack of tissue trauma, we found significant advantages in using Biolase’s WaterLase technology. We anticipate that our system will have major advantages over traditional phacoemulsification and should create a new standard for safety, speed and effectiveness in cataract removal,” Auris chairman & CEO Dr. Frederic Moll said in prepared remarks.